Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
Testosterone supplementation: For whom and when?
Sexuality, Reproduction & Menopause, 10/08/09
Khera M – Evidence shows that testosterone, added to estrogen therapy (ET), improves sexual function in women and may improve bone health. However, the absence of an FDA–approved agent, off–label use raises questions about patient selection, dosing, and safety. Approval of testosterone–containing preparations has been deferred pending confirmation of long–term safety assessments (2–5 years). Evidence suggests that testosterone supplementation does not increase the risk of breast cancer; it may have a protective effect on breast tissue. A longer time to disease progression and a higher response rate is observed when androgens are added to anti–estrogen therapy. Long–term androgen administration does not have significant, adverse effects on female breast tissue. Nevertheless, testosterone can still be aromatized to estrogen; patients with a history of estrogen–sensitive breast cancer should be discouraged from treatment. No convincing data suggest that testosterone use increases the risk of cardiovascular events in women. Although oral methyltestosterone has been shown to reduce HDL and raise LDL levels in women, this effect is not seen in association with other forms of testosterone. Finally, no evidence indicates that testosterone supplementation increases the risk of endometrial cancer.
Related Articles
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Relevance Score: 95%
Testosterone and biological characteristics of breast cancers in postmenopausal women
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 94%
Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets
European Journal of Endocrinology, 11/17/09
Relevance Score: 91%
NIH-Supported Trial to Study Testosterone Therapy in Older Men
MedLinePlus, 11/04/09
Relevance Score: 91%
NIH-Supported Trial to Study Testosterone Therapy in Older Men
NIH, 11/03/09
Relevance Score: 91%
Today in Women`s Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment
Medical Principles and Practice, 12/10/09
Impact of gender in primary prevention of coronary heart disease with statin therapy: A meta-analysis
International Journal of Cardiology, 12/10/09
Detecting breast cancer in a general practice - Like finding needles in a haystack?
Australian Family Physician, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


